Nektar Therapeutics Form 4 insider transactions

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, received 16,500 shares of common stock on July 24, 2026.

Howard W Robin, President & CEO and a Director of Nektar Therapeutics, received 57,200 shares of common stock on July 24, 2026.

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky reported a transaction involving Nektar Therapeutics common stock under a Rule 10b5-1 trading plan.

Nektar Therapeutics President & CEO, Howard W. Robin, reported the sale of company stock totaling over 20,000 shares across multiple transactions executed between June 16-17, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Chief R&D Officer Jonathan Zalevsky sold 5,538 shares of Nektar Therapeutics common stock via a Rule 10b5-1 trading plan.

Chief R&D Officer Jonathan Zalevsky sold 199 shares of Nektar Therapeutics to cover tax withholding obligations related to RSU vesting.

Nektar Therapeutics CEO Howard W. Robin sold 444 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 3,867 shares of common stock for a weighted average price of $35.67 per share under a pre-arranged trading plan.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, received a grant of 6,250 restricted stock units and 25,000 stock options, vesting over four years.

Nektar Therapeutics' President and CEO, Howard W. Robin, was granted 21,667 restricted stock units and 86,667 stock options as part of a pre-planned equity compensation.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, reported the vesting of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Nektar Therapeutics' Chief Legal Officer, Mark Andrew Wilson, reported the vesting of restricted stock units and stock options, alongside a non-discretionary sale of shares to cover tax obligations.

Nektar Therapeutics CEO Howard W. Robin reported the vesting of restricted stock units and stock options, alongside a tax-related sale of common stock.

Nektar Therapeutics Director Roy A. Whitfield was granted 8,000 stock options with an exercise price of $56.9, vesting over one year starting September 30, 2025.

Nektar Therapeutics director R. Scott Greer was granted 8,000 stock options with an exercise price of $56.90, which will vest over a one-year period starting September 30, 2025.

Nektar Therapeutics director Robert Chess was granted 8,000 stock options with an exercise price of $56.90, vesting over one year.

Nektar Therapeutics director Diana Brainard was granted 8,000 stock options with an exercise price of $56.90, vesting monthly over one year starting September 30, 2025.

Nektar Therapeutics director Jeffrey Robert Ajer was granted 8,000 stock options with an exercise price of $56.90, vesting over one year starting September 30, 2025.

Nektar Therapeutics' President and CEO, Howard W. Robin, sold 6,666 shares of common stock on September 9, 2025, through a pre-arranged 10b5-1 trading plan.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 1,721 shares of common stock on September 4, 2025, through a pre-arranged 10b5-1 trading plan.

Nektar Therapeutics' President and CEO, Howard W. Robin, sold a total of 11,832 shares of common stock in early September 2025 under a pre-arranged trading plan.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 485 shares of common stock for a weighted average price of $30.1 per share pursuant to a pre-arranged Rule 10b5-1 trading plan.

Nektar Therapeutics' President and CEO, Howard W. Robin, sold 1,500 shares of common stock for approximately $30.16 per share under a pre-arranged trading plan.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold shares to cover tax obligations related to RSU vesting and acquired new stock options.

Nektar Therapeutics' Chief Legal Officer, Mark Wilson, sold shares to cover tax obligations related to RSU vesting and saw 21,666 stock options vest.

Nektar Therapeutics' President & CEO, Howard W. Robin, sold 1,573 shares to cover tax obligations related to RSU vesting, while 86,666 stock options vested following performance target achievement.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 10,712 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Mark Andrew Wilson, Chief Legal Officer of Nektar Therapeutics, sold 9,996 shares of common stock on May 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Nektar Therapeutics CEO Howard W. Robin sold 23,208 shares of common stock on May 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 10,300 shares of common stock to cover tax withholding obligations related to vesting RSUs.